Literature DB >> 24096050

Perforin and granzymes work in synergy to mediate cholangiocyte injury in experimental biliary atresia.

Pranavkumar Shivakumar1, Reena Mourya1, Jorge A Bezerra2.   

Abstract

BACKGROUND & AIMS: Biliary atresia represents obstructive cholangiopathy in infants progressing rapidly to cirrhosis and end-stage liver disease. Activated NK cells expressing Nkg2d have been linked to bile duct injury and obstruction by establishing contact with cholangiocytes. To define the mechanisms used by cytotoxic cells, we investigated the role of perforin and granzymes in a neonatal mouse model of rotavirus (RRV)-induced biliary atresia.
METHODS: We used complementary cell lysis assays, flow cytometric analyses, quantitative PCRs and in vivo systems to determine the mechanisms of bile duct epithelial injury and the control of the tissue phenotype in experimental biliary atresia.
RESULTS: RRV-infected hepatic NK and CD8 T cells increased the expression of perforin and injured cholangiocytes in short-term culture in a perforin-dependent fashion. However, the loss of perforin in vivo delayed but did not prevent the obstruction of bile ducts. Based on the increased expression of granzymes by perforin-deficient cytotoxic cells in long-term cytolytic assays, we found that the inhibition of granzymes by nafamostat mesilate (FUT-175) blocked cholangiocyte lysis. Administration of FUT-175 to perforin-deficient mice after RRV infection decreased the development of jaundice, minimized epithelial injury, and improved long-term survival. However, the inhibition of granzymes alone in wild-type mice was not sufficient to prevent the atresia phenotype in newborn mice. In infants with biliary atresia, hepatic Granzymes A and B mRNA, but not Perforin, increased at the time of portoenterostomy.
CONCLUSIONS: Perforin and granzymes have complementary roles mediating epithelial injury by NK and CD8 T cells. The prevention of experimental biliary atresia can only be achieved by inhibiting both granules.
Copyright © 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Children; Cholangiocyte; Cholestasis; Immunity; Jaundice; Liver; Neonates; PKO; RRV; Rhesus rotavirus type A; WT; ffu; fluorescence-forming units; perforin knockout; wild type

Mesh:

Substances:

Year:  2013        PMID: 24096050      PMCID: PMC3946990          DOI: 10.1016/j.jhep.2013.09.021

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  26 in total

1.  Dendritic cells regulate natural killer cell activation and epithelial injury in experimental biliary atresia.

Authors:  Vijay Saxena; Pranavkumar Shivakumar; Gregg Sabla; Reena Mourya; Claire Chougnet; Jorge A Bezerra
Journal:  Sci Transl Med       Date:  2011-09-28       Impact factor: 17.956

Review 2.  Mechanisms of granule-dependent killing.

Authors:  S P Cullen; S J Martin
Journal:  Cell Death Differ       Date:  2007-11-02       Impact factor: 15.828

3.  Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs.

Authors:  Todd A Fehniger; Sheng F Cai; Xuefang Cao; Andrew J Bredemeyer; Rachel M Presti; Anthony R French; Timothy J Ley
Journal:  Immunity       Date:  2007-05-31       Impact factor: 31.745

4.  Alternative mechanisms of respiratory syncytial virus clearance in perforin knockout mice lead to enhanced disease.

Authors:  S Aung; J A Rutigliano; B S Graham
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

5.  Extracellular matrix remodeling by human granzyme B via cleavage of vitronectin, fibronectin, and laminin.

Authors:  Marguerite S Buzza; Laura Zamurs; Jiuru Sun; Catherina H Bird; A Ian Smith; Joseph A Trapani; Christopher J Froelich; Edouard C Nice; Phillip I Bird
Journal:  J Biol Chem       Date:  2005-04-19       Impact factor: 5.157

Review 6.  Advances in biliary atresia: from patient care to research.

Authors:  J L Santos; E Carvalho; J A Bezerra
Journal:  Braz J Med Biol Res       Date:  2010-04-30       Impact factor: 2.590

Review 7.  Biliary atresia: a new immunological insight into etiopathogenesis.

Authors:  Toshihiro Muraji; David L Suskind; Naoki Irie
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2009-12       Impact factor: 3.869

8.  Biliary atresia is associated with CD4+ Th1 cell-mediated portal tract inflammation.

Authors:  Cara L Mack; Rebecca M Tucker; Ronald J Sokol; Frederick M Karrer; Brian L Kotzin; Peter F Whitington; Stephen D Miller
Journal:  Pediatr Res       Date:  2004-05-05       Impact factor: 3.756

9.  Temporal-spatial activation of apoptosis and epithelial injury in murine experimental biliary atresia.

Authors:  Nissa Erickson; Sujit Kumar Mohanty; Pranavkumar Shivakumar; Gregg Sabla; Ranajit Chakraborty; Jorge A Bezerra
Journal:  Hepatology       Date:  2008-05       Impact factor: 17.425

Review 10.  Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma.

Authors:  Wendy Anne Boivin; Dawn Michelle Cooper; Paul Ryan Hiebert; David James Granville
Journal:  Lab Invest       Date:  2009-09-21       Impact factor: 5.502

View more
  12 in total

Review 1.  Pathogenesis of biliary atresia: defining biology to understand clinical phenotypes.

Authors:  Akihiro Asai; Alexander Miethke; Jorge A Bezerra
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-05-26       Impact factor: 46.802

2.  Preferential TNFα signaling via TNFR2 regulates epithelial injury and duct obstruction in experimental biliary atresia.

Authors:  Pranavkumar Shivakumar; Tatsuki Mizuochi; Reena Mourya; Sridevi Gutta; Li Yang; Zhenhua Luo; Jorge A Bezerra
Journal:  JCI Insight       Date:  2017-03-09

3.  Live cell evaluation of granzyme delivery and death receptor signaling in tumor cells targeted by human natural killer cells.

Authors:  Alexandra C Vrazo; Adrianne E Hontz; Sarah K Figueira; Braeden L Butler; Julie M Ferrell; Brock F Binkowski; Jinzhu Li; Kimberly A Risma
Journal:  Blood       Date:  2015-06-29       Impact factor: 22.113

4.  IL13 and periostin in active fibrogenic areas of the extrahepatic bile ducts in biliary atresia patients.

Authors:  Yuki Sengoku; Mayumi Higashi; Kazuya Nagayabu; Shohei Takayama; Shigehisa Fumino; Shigeyoshi Aoi; Taizo Furukawa; Tatsuro Tajiri
Journal:  Pediatr Surg Int       Date:  2022-09-23       Impact factor: 2.003

5.  Functional and structural features of cholangiocytes in health and disease.

Authors:  Luca Maroni; Bai Haibo; Debolina Ray; Tianhao Zhou; Ying Wan; Fanyin Meng; Marco Marzioni; Gianfranco Alpini
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2015-07-01

6.  Natural killer cells promote long-term hepatobiliary inflammation in a low-dose rotavirus model of experimental biliary atresia.

Authors:  James E Squires; Pranavkumar Shivakumar; Reena Mourya; Kazuhiko Bessho; Stephanie Walters; Jorge A Bezerra
Journal:  PLoS One       Date:  2015-05-19       Impact factor: 3.240

Review 7.  Innate Immunity and Pathogenesis of Biliary Atresia.

Authors:  Ana Ortiz-Perez; Bryan Donnelly; Haley Temple; Greg Tiao; Ruchi Bansal; Sujit Kumar Mohanty
Journal:  Front Immunol       Date:  2020-02-25       Impact factor: 7.561

8.  Loss of CD28 expression by liver-infiltrating T cells contributes to pathogenesis of primary sclerosing cholangitis.

Authors:  Evaggelia Liaskou; Louisa E Jeffery; Palak J Trivedi; Gary M Reynolds; Shankar Suresh; Tony Bruns; David H Adams; David M Sansom; Gideon M Hirschfield
Journal:  Gastroenterology       Date:  2014-04-12       Impact factor: 22.682

9.  Cxcr2 signaling and the microbiome suppress inflammation, bile duct injury, and the phenotype of experimental biliary atresia.

Authors:  Junbae Jee; Reena Mourya; Pranavkumar Shivakumar; Lin Fei; Michael Wagner; Jorge A Bezerra
Journal:  PLoS One       Date:  2017-08-01       Impact factor: 3.240

10.  T-Bet Deficiency Attenuates Bile Duct Injury in Experimental Biliary Atresia.

Authors:  Sujit K Mohanty; Bryan Donnelly; Haley Temple; Alexander Bondoc; Monica McNeal; Greg Tiao
Journal:  Cells       Date:  2021-12-08       Impact factor: 7.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.